AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of ...

AstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its primary goals. The British-Swedish pharma giant on Tuesday said ...

A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.

AstraZeneca breast cancer drug trial fails to extend lives of patients. Britain's largest pharma firm said drug did not 'achieve statistical significance' ...

(Reuters) - London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve ...

Today’s results suggest that AstraZeneca’s persistence with zibotentan has paid off after the drug suffered a pair of late-stage trial failures in prostate cancer in 2010 and 2011.

AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...